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THE effects  of  IPD-1151T  on  the  expression  of  co-
stimulatory molecules, CD40, CD80 and CD86, were
investigated  in  vivo using  mice  with  allergic  dis-
orders.  BALB/c  mice  were  immunized  intraperito-
neally  with  two  doses  of  dinitrophenylated ovalbu-
min (DNP-OVA) at 1-week intervals. These mice then
were treated intraperitoneally with 100 m g/kg of IPD-
1151T once a day for 14 days, starting 7 days after the
first  immunization.  On  day  21,  some  mice  were
challenged  intraperitoneally  with  DNP-OVA  and the
other  mice  were  not  challenged.  All  mice  were
autopsied on day 22 and assayed for immunoglobulin
E, interleuken (IL)-4 and IL-5 productions following
DNP-OVA  immunization.  The  intraperitoneal  treat-
ment with IPD-1151T  strongly suppressed immuno-
globulin E contents in serum, which were enhanced
by DNA-OVA immunization. IPD-1151T also caused a
decrease  in  both  IL-4  and  IL-5  levels  in  splenic
lymphocytes. We next examined the influence of IPD-
1151T  on  co-stimulatory  molecule  expression  on
splenic lymphocytes. IPD-1151T caused suppression
of  CD40  and  CD86  expression;  however,  the  treat-
ments did not affect CD80 expression.
Key  words:  IPD-1151T,  CD40,  CD86,  CD80,  Mouse,
Splenocyte, In vivo
Introduction
IPD-1151T (suplatast tosilate) is an anti-allergic agent
that suppresses several processes in the development
of allergic disorders. This agent inhibits immunoglo-
bulin (Ig)E antibody hyper-production and eosinophi-
lia.1,2 It is also reported that IPD-1151T can suppress
the  production  of  interleukin  (IL)-4  and  IL-5  in
response to antigenic stimulation.3
It is now recognized that two distinct signals are
given in a full activation of the immune system against
allergen. The first signal is provided by the ligation of
the  T-cell  receptor  and  the  peptide–major  histo-
compatibility complex class II molecule complex, and
the second is the interaction between co-stimulatory
molecules  expressed  on  antigen  presenting  cells
(APC), and their ligands on T and B lymphocytes.4,5
There is much evidence that expression of the co-
stimulatory  molecules,  CD40,  CD80  and  CD86,  on
peripheral blood leukocytes from patients with aller-
gic disease was upregulated compared with normal
subjects,6–8 suggesting the importance of these mole-
cules in  the induction and the development of the
disease. However, the influences of IPD-1151T on the
co-stimulatory molecule expression are poorly under-
stood. It is generally accepted that immunization of
mice with antigen absorbed to Al(OH)3 can induce IgE
hyper-production and enhance the ability of lympho-
cyte to produce IL-4 and IL-5, which are observed in
human  allergic  disorders. Therefore,  we  examined
whether IPD-1151T has a suppressive activity on the
expression of these molecules using mice immunized
with antigen absorbed to Al(OH)3, and whether the




BALB/c male mice, 5 weeks of age, were purchased
from Charles River Japan Inc. (Atsugi, Japan).
Immunization
Ten BALB/c mice were immunized by intraperitoneal
injection of 5.0mg/ml of dinitrophenylated ovalbumin
(DNP-OVA) absorbed on 4mg Al(OH)3, and boostered
intraperitoneally with the same dose of antigen 7 days
later.  Five  mice were intraperitoneally administered
the same dose of the  antigen (challenged)  21  days
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were not (not challenged).
Drugs and treatments
IPD-1151T was provided in a pure powder by TAIHO
Co., Ltd. (Tokyo, Japan). It was dissolved in distilled
water  and  then  diluted  in  saline  to  the  desired
concentration. The  immunized  mice  were  intraper-
itoneally administered 100mg/kg/ml per day of IPD-
1151T  for  14  days  starting  7  days  after  the  first
immunization. The control mice received saline in the
same manner.
Assay for serum total IgE
The  blood was  obtained from  the  mice  by  cardiac
puncture under ether anesthesia 22 days after the first
immunization. After clotting, the serum was obtained
and  total  serum  IgE  levels  were  measured  using
mouse  IgE  enzyme-linked  immunosorbent  assay
(ELISA) kits (YAMASA Co., Ltd., Chiba, Japan) accord-
ing to the manufacturer’s recommended procedures.
The assay was performed in duplicate and the results
were  expressed  as  the  mean  (ng/ml)  ±  SE  of  five
individual mice.
Preparation of spleen cell suspension
The spleens were obtained from  mice killed under
ether anesthesia, and placed in RPMI-1640 medium,
and  pressed  through  a  60-gauge  steel  mesh  to
produce a single cell suspension. After centrifugation
at  1000r.p.m.  for  10min  at  4°C,  the  pelleted  cells
were treated with 0.15M Tris–0.75% NH4Cl solution
for  10min  to  lyse  red  blood  cells.  After  filtering
through  a  200-gauge  steel  mesh,  the  residual  cells
were  washed  three  times  and  suspended  in  phos-
phate-buffered saline (PBS) at a concentration of 5 ´
106 cells/ml (for cytokine assay) or 1 ´ 106 cells/ml
(for flow cytometry)
Assay for IL-4 and IL-5
IL-4 and IL-5 concentrations were assayed using mouse
IL-4  and  IL-5  ELISA  kits  (R&D  system  Co.,  Ltd.,
Minneapolis,  MN,  USA)  according  to  the  manu-
facturer’s recommended procedures. The ELISA was
carried out in duplicate and the results were expressed
as the mean (pg/ml) ± SE of five individual mice.
Monoclonal antibodies and flowcytometry
The monoclonal antibodies (mAbs) used in this study
were  anti-mouse  CD16/CD32mAb,  flourescein  iso-
thiocyanate (FITC)-conjugated anti-mouse CD40mAb
(hamster IgM), phycoerythrin-conjugated anti-mouse
CD80mAb (hamster IgG), and FITC-conjugated anti-
mouse CD86mAb (rat IgG2a). They were purchased
from  PharMingen  (San  Dieago,  CA,  USA). To  block
non-specific adherence of antibodies to murine Fcg
III/II  receptors,  spleen  cells  (1  ´ 106/ml)  were
incubated with 1.0mg of anti-mouse CD16/CD32mAb
for 10min  at 4°C, washed, and labeled with either
anti-mouse CD40, CD80, or CD86 for 30min in an ice-
cold  water  bath.  After  washing  once,  fluorescent
staining was analyzed immediately by flow cytometry
on a FACScan (Becton Dickinson, Mountain View, CA,
USA). Dead cells were gated out by means of forward
scatter  (FCS)  and  sideward  scatter  (SSC).  Fluores-
cence of 106 cells was recorded and the findings were
analyzed  with  Consort  30  software  (Becton
Dickinson).
Statistical analysis
The findings were expressed as the means ± SE and
analyzed for significant differences using Wilcoxon’s
test.
Results
Effect of IPD-1151T on IgE antibody formation
The first experiments were carried out to examine the
influence of IPD-1151T on IgE antibody formation.  The
results are summarized in Table 1. DNA-OVA immuniza-
tion  enhanced  serum  IgE  levels  as  compared  with
normal control. Treatment of  immunized  mice (not
challenged) with IPD-1151T caused a marked reduc-
tion  in  IgE  levels:  the  level  of  this  antibody  in
immunized  and  treated  mice  (not  challenged)  was
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Table 1. Effects of IPD-1151T on production of IgE, IL-4 and IL-5 in BALB/c mice immunized by DNP-OVA
Type of mice examined Treatment IgE (ng/ml ± SE) IL-4 (pg/ml ± SE) IL-5 (pg/ml ± SE)
Healty control none 25.1 ± 17.4 12.3 ± 4.5 0.4 ± 0.1
Non-challenged Saline 351.7 ± 73.5 28.2 ± 6.0 2.5 ± 0.5
IPD-1151T 32.4 ± 25.2** 10.8 ± 2.5* 0.3 ± 0.3*
Challenged Saline 365.3 ± 95.0 39.7 ± 5.3 3.4 ± 0.1
IPD-1151T 52.9 ± 24.9* 22.9 ± 5.8* 1.0 ± 0.2*
Each value is the mean ± SE of five individual mice.
* Significant as compared with saline-treated mice (p<0.05).
** Significant as compared with saline-treated mice (p<0.01).IPD-1151T on co-stimulatory molecule
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FIG. 1. Suppressive effect of IPD-1151T on co-stimulatory molecule expression on splenocytes obtained from BALB/c mice with
allergic disorders. BALB/c mice were immunized intraperitoneally with two doses of 5.0mg/ml of dinitrophenylated ovalbumin
absorbed on 4mg of Al(OH)3 at 1-week intervals. The mice were treated intraperitoneally with 100mg/kg of IPD-1151T for 14
days, starting after the first immunization. Splenocytes were obtained from mice 24h after the challenge with the same dose
of  antigen,  and  assayed  for  co-stimulatory  molecule  expressions.  [––––––],  Saline-treated  control  mice;  [– – – –],  IPD-
1151T-treated mice. Left-hand side, Non-challenged mice; right-hand side, challenged mice.nearly  identical to that in normal control (P>0.05).
Moreover,  the  data  in  Table  1  also  showed  that
treatment  with  IPD-1151T  for  14  days  caused  a
significant  decrease  in  IgE  contents,  which  was
enhanced by DNA-OVA challenge immunization.
Effect of IPD-1151T on IL-4 and IL-5 production
The  second set  of  experiments  was  undertaken to
examine the influence of IPD-1151T on IL-4 and IL-5
production. As shown in Table 1, IPD-1151T treatment
induced  significant  suppression  of  IL-4  and  IL-5
contents  in  splenocytes,  which  were  increased  by
DNA-OVA immunization.  Furthermore, this suppres-
sive  effect  of  IPD-1151T  was  also  observed  in
challenged mice (Table 1).
Effects of IPD-1151T on co-stimulatory
molecule expression on splenocytes in vivo
The final set of experiments was designed to examine
the influence of IPD-1151T on CD40, CD80 and CD86
expressions on splenocytes. The results are shown in
Fig. 1, which is one typical profile among the results
obtained from five different mice. The left-hand side
of  Fig.  1  shows that, in  non-challenged  mice,  IPD-
1151T markedly suppressed the third peak of CD40
(but not CD80 and CD86) molecule expression that
was enhanced by DNP-OVA immunization. In contrast
to the results obtained in non-challenged mice, IPD-
1151T  treatment  in  challenged  mice  (1,  right-hand
side) caused a slight decrease in fluorescence inten-
sity of CD40. However, IPD-1151T exerted a marked
suppression in the second peak of CD86 observed in
challenged mice.
Discussion
It is generally accepted that antigen-specific immune
responses  are  initiated  after  the  collaboration  of T
cells  with APC.9 Recently,  it  was  reported  that  an
optimal T-cell  activation requires  another cell-to-cell
interaction. The first signal transduction is due to the
interaction  between  the T-cell  receptor  and  major
histocompatibility complex class II molecule with an
antigenic determinant. The second signal is provided
by the direct contacts of co-stimulatory molecules on
T cells with their ligands on APC. The signal through
the binding of CD28/CTLA4 on T cells with its ligands,
CD80 and CD86, on APC is a crucial co-stimulatory
pathway.9,10
Furthermore,  engagement  of  the  B-cell  marker
CD40 by its ligand CD40L is also recognized to play an
important role in T-cell-dependent isotype switching
to IgE.11 Clinical observations in patients with allergic
disorders reveal  the  upregulation  of  co-stimulatory
molecule  expressions  on  peripheral  blood  leuko-
cytes,7,8,12 suggesting  the  importance  of  co-stim-
ulatory molecules in the initiation of allergic diseases.
In this study, we found that IPD-1151T inhibited IL-4
and  IL-5 production by T  helper  2  (Th2)  cells  and
suppressed  production  of  IgE. These  findings  sug-
gested that IPD-1151T has a suppressive effect on the
CD40 expression on B cells and, thereby, results in
inhibition of IgE production.
Moreover,  the  B7  markers, CD80  and  CD86,  are
accessory molecules  that play  an important role in
T-cell and B-cell interactions in addition to CD40.4,5
Recent studies in mice have suggested that generation
of Th2 cells mainly depend on the interaction of B-cell
antigen CD86 with T-cell antigen CD28.13,14 In addi-
tion,  studies  of  human  T  cells  have  reported  the
importance of CD86 in Th2 cell activation, such as
proliferation and cytokine secretion, in response to
stimulation with allergen.15 In addition, it has been
revealed that the expression of CD86 (but not CD80)
was upregulated in allergic patients such as asthma,6
allergic  dermatitis7 and allergic  rhinitis12 compared
with non-allergic subjects. Accordingly, this molecule
is suggested to be an important co-stimulatory mole-
cule in allergic responses.
Therefore, the  present  findings  may  demonstrate
that  IPD-1151T  prevents  APC  and  T-cell  contact
through the suppression of CD40 and CD86 molecule
expression, and results  in favorable modification of
the clinical condition of allergic patients. At present,
the reason why IPD-1151T administration suppressed
CD40  molecule  expression  in  non-challenged  mice
and CD86 molecule expression in challenged mice is
unclear.  However,  these  findings  probably  suggest
that  CD40  collaborate  with  CD40L  prior  to  the
binding  of CD86  and  CD28/CTLA-4 in  the  antigen-
specific immune responses. The observations in the
present study  could be  available for  the analysis of
anti-allergic  mechanisms  and  for  the  treatment  of
patients with allergic disorders. Additional and vari-
ous  studies  should  be  carried  out  to  clarify  this
problem.
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